Castle Creek Biosciences Announces First Patient Dosed in Phase 1/2 Clinical Trial of FCX-013 Gene Therapy for Treatment of Moderate to Severe Localized Scleroderma
News, Events & Presentations

Castle Creek Biosciences Announces First Patient Dosed in Phase 1/2 Clinical Trial of FCX-013 Gene Therapy for Treatment of Moderate to Severe Localized Scleroderma

Study targets a chronic autoimmune skin disorder affecting approximately 50,000 patients in the U.S.

Read More

Corporate Fact Sheet

Castle Creek Biosciences, Inc., a privately-held, clinical-stage cell and gene therapy company, is leveraging its proprietary fibroblast technology platform to develop and commercialize innovative personalized therapies for underserved disorders with high unmet medical needs. Castle Creek Biosciences is a portfolio company of Paragon Biosciences.

Read More

Cell & Gene Meeting on the Mesa

A Virtual Event, October 12-16

Read More

2020 Pediatric Dermatology Research Alliance (PeDRA) Annual Conference

A Virtual Event, October 22-23

Read More

Fall Clinical Dermatology Meeting 2020

A Virtual Event, October 29 – November 1

Read More

Philadelphia Magazine’s NextHealth PHL

9 Philly Companies on the Cutting Edge of Cell and Gene Therapy Innovation

Read More

Castle Creek Biosciences Announces $75 Million Investment to Advance Development of Multiple Gene Therapy Candidates for Rare Diseases

Leveraging proprietary technology and manufacturing platform to develop transformative gene therapies for multiple rare diseases with high unmet needsPipeline led by Phase 3 gene therapy candidate for treatment of recessive dystrophic epidermolysis bullosa (RDEB), with a BLA filing targeted for 2021Backed by world-class group of biotech operators and investorsCastle Creek Biosciences, Inc., a privately held, […]

Read More

Rare Daily’s RARECast

“Acquisition Combines Two Pipelines for Rare Skin Diseases” John Maslowski, CEO, Castle Creek Biosciences

Read More

Philadelphia Magazine’s NextHealth PHL

NextUp: “The Company Using Gene Therapy to Cure Rare Skin Conditions” John Maslowski, CEO, Castle Creek Biosciences

Read More

Rare Disease Innovation and Partnering Virtual Summit 2020

A Virtual Event, December 1-4

Read More